Table 2.
Patient | Family | Age | Mutation 1 | Mutation 2 | Mutation type2 | Plasma [FGF23], RU/mL3 |
---|---|---|---|---|---|---|
1 | A | 3 yrs | p.R1314W | p.R1314W | MS/MS | 59 |
2 | A | 6 yrs | p.R1314W | p.R1314W | MS/MS | 97 |
3 | B | 1 mo | c.2787+1G>T | c.3736−1G>A | SS/SS | NT5 |
4 | C | 5 yrs | p.R391G | ND1 | MS/ND | 83 |
5 | D | 1 mo | p.R1141* | c.346-6G>A | NS/SS4 | NT |
6 | E | 1 mo | c.3692 insTT | ND | FS/ND | 374 |
7 | F | 1 mo | p.R760W | del23-29 | MS/del | 1430 |
ND, not detected.
MS, missense; SS, splice site; NS, nonsense; FS, frame shift
FGF23 normal range is < 230 RU/mL for ages 3 months to 17 years. Values greater than 900 RU/mL are present in infants.
The effects of the c.346-6G>A mutation on splicing have not been experimentally confirmed
NT, not tested as serum sample was not available